Radiopharm's Brain Cancer Imaging Agent Shows 92% Success in Phase 2 Trial
Radiopharm Theranostics (RADX) reports promising interim results for RAD 101, a novel brain metastases imaging agent, with 92% accuracy matching MRI scans in clinical trial.
/ 907 items
#Healthcare↓
Greenwich LifeSciences Shows Promising Breast Cancer Treatment Results
Greenwich LifeSciences reports 80% reduction in breast cancer recurrence rates in FLAMINGO-01 trial using GLSI-100 immunotherapy treatment.
BofA Upgrades Bristol Myers to Buy on Strong Pipeline Outlook
Bank of America upgrades Bristol Myers Squibb to Buy, raising its price target to $61, citing a strong R&D pipeline and multiple upcoming catalysts through 2026.
Adaptive Biotechnologies Partners with Pfizer on Immune Disease Research
Adaptive Biotechnologies signs two deals with Pfizer worth up to $890M to discover rheumatoid arthritis treatments and share immune system data for AI-powered drug development.
Immunome's Desmoid Tumor Drug Shows 84% Success in Trial
Immunome's (IMNM) Varegacestat reduces disease progression by 84% in Phase 3 desmoid tumor trial. FDA submission planned for Q2 2026. Once-daily oral pill.
First CAR T Therapy for Stiff Person Syndrome Shows Success
Kyverna Therapeutics (KYTX) announces positive results from clinical trial of miv-cel CAR T-cell therapy for stiff person syndrome, potentially the first FDA-approved treatment for this rare autoimmune disease.